← Back

Chongqing Xishan Science&Technology Co. Ltd. A

Chongqing Xishan Science & Technology Co., Ltd. develops, manufactures, sells, and services digital minimally invasive surgical equipment and medical consumables in China and internationally. Its offerings include powered surgical instruments such as micromotors, handpieces, attachments, shavers, burs, saw blades, and perforators, as well as vacuum-assisted breast biopsy products including control modules, handpieces, probes, and canisters. The company also provides UHD endoscopy systems, ultrasonic bone scalpel systems, RF/HF electrosurgical units and electrodes, and plasma electrosurgical units and electrodes. Founded in 1999, it is headquartered in Chongqing, China.

Country
Price · split & dividend adjusted
News & notes moving 688576.CG
688576.CG

Xishan Technology's 2026 interim report shows net loss of 25.4613 million yuan, swinging from profit to loss

Xishan Technology released its 2026 interim report. The company's total operating revenue was 120 million yuan, down 22.87% year-on-year. Net profit attributable to the parent company was negative 25.4613 million yuan, swinging from profit to loss, down 174.05% year-on-year. Net cash flow from operating activities was negative 52.0412 million yuan, down 396.95% year-on-year. The company's asset-liability ratio was 6.80%, gross margin was 60.30%, down 5.01 percentage points from the same period last year. ROE was negative 1.51%, and diluted earnings per share was negative 0.38 yuan.
Jiemian·19dRead more →
688576.CG

Xishan Technology Posts First-Half Loss of 25.46 Million Yuan, Down 174.1% Year on Year

Xishan Technology released its 2026 interim report. First-half operating revenue was 120 million yuan, down 22.9% year on year, with a loss of 25.46 million yuan, a decline of 174.1% from a year earlier. Second-quarter operating revenue was 47.75 million yuan, down 46.4% year on year, while net profit attributable to the parent company showed a loss of 32.75 million yuan, down 243.0% year on year. The company said the revenue decline was mainly due to fluctuations in end-market demand caused by changes in the macro environment and industry regulatory policies, as well as adjustments to its marketing system. Meanwhile, international revenue reached 12.34 million yuan, an increase of more than 150% year on year, and research and development spending accounted for 25.68% of revenue, up 9.72 percentage points from the same period last year.
财中社·22dRead more →